Idiopathic hyposmia as a preclinical sign of Parkinson's disease
MM Ponsen, D Stoffers, J Booij… - Annals of Neurology …, 2004 - Wiley Online Library
Olfactory dysfunction is an early and common symptom in Parkinson's disease (PD). In an
effort to determine whether otherwise unexplained (idiopathic) olfactory dysfunction is …
effort to determine whether otherwise unexplained (idiopathic) olfactory dysfunction is …
Gender differences in Parkinson's disease
…, WJG Oyen, KL Leenders, S Eshuis, J Booij… - Journal of Neurology …, 2007 - jnnp.bmj.com
Objective: To investigate gender differences in basic disease characteristics, motor deterioration
and nigrostriatal degeneration in Parkinson’s disease (PD). Methods: We studied 253 …
and nigrostriatal degeneration in Parkinson’s disease (PD). Methods: We studied 253 …
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study
Background Dementia with Lewy bodies (DLB) needs to be distinguished from other types
of dementia because of important differences in patient management and outcome. Current …
of dementia because of important differences in patient management and outcome. Current …
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2
…, S Asenbaum, T Vander Borght, J Booij… - European journal of …, 2009 - Springer
These guidelines summarize the current views of the European Association of Nuclear
Medicine Neuroimaging Committee (ENC). The purpose of the guidelines is to assist nuclear …
Medicine Neuroimaging Committee (ENC). The purpose of the guidelines is to assist nuclear …
Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell
HW Berendse, J Booij, CMJE Francot… - Annals of Neurology …, 2001 - Wiley Online Library
By the time a clinical diagnosis of Parkinson's disease (PD) is made, a significant loss of
dopaminergic neurons has already occurred. Identifying patients in the period between the …
dopaminergic neurons has already occurred. Identifying patients in the period between the …
Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers
J Lavalaye, J Booij, L Reneman, JBA Habraken… - European journal of …, 2000 - Springer
Dopamine transporter imaging is a valuable tool to investigate the integrity of the dopaminergic
neurons. To date, several reports have shown an age-associated decline in dopamine …
neurons. To date, several reports have shown an age-associated decline in dopamine …
EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2
J Darcourt, J Booij, K Tatsch, A Varrone… - European journal of …, 2010 - Springer
These guidelines summarize the current views of the European Association of Nuclear
Medicine Neuroimaging Committee (ENC). The aim of the guidelines is to assist nuclear …
Medicine Neuroimaging Committee (ENC). The aim of the guidelines is to assist nuclear …
The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other …
J Booij, JD Speelman, MWIM Horstink… - European journal of …, 2001 - Springer
[ 123 I]FP-CIT (N-ω-fluoropropyl-2β-carbomethoxy-3β-{4-iodophenyl}nortropane) has been
developed successfully as a radioligand for single-photon emission tomography (SPET) …
developed successfully as a radioligand for single-photon emission tomography (SPET) …
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3‐year European multicenter study with repeat [123I]FP‐CIT SPECT
…, J Kulisevsky, L Cunha, D Costa, J Booij… - Movement …, 2009 - Wiley Online Library
Overdiagnosis of Parkinson's disease (PD) is suggested by specialist review of community
diagnosis, and in postmortem studies. In specialist centers 4 to 15% of patients entered into …
diagnosis, and in postmortem studies. In specialist centers 4 to 15% of patients entered into …
SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0
…, MJR Janssen, N Bohnen, J Booij… - Journal of Nuclear …, 2012 - Soc Nuclear Med
Nv-fluoropropyl-2b-carbomethoxy-3b-(4-123I-iodophenyl) nortropane (123I-ioflupane) is a
molecular imaging agent used to demonstrate the location and concentration of dopamine …
molecular imaging agent used to demonstrate the location and concentration of dopamine …